Maintenance therapy improves the survival outcomes of patients with metastatic nasopharyngeal carcinoma responding to first-line chemotherapy: a multicentre, randomized controlled clinical study

被引：0
|
作者：
Ying Lu
Haixin Huang
Hui Yang
Xiaohua Hu
Meilian Liu
Changjie Huang
Xianbin Feng
Xishan Chen
Zhou Jiang
机构：
[1] The Fourth Affiliated Hospital of Guangxi Medical University,Department of Oncology
[2] The First Affiliated Hospital of Guangxi Medical University,Department of Oncology
[3] Affiliated Hospital of Guilin Medical College,Department of Oncology
[4] The Third Affiliated Hospital of Guangxi Medical University,Department of Oncology
[5] Liuzhou Hospital of Traditional Chinese Medicine,Department of Oncology
来源：
Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷
关键词：
Nasopharyngeal carcinoma; Tegafur/gimeracil/oteracil; Maintenance therapy; Epstein‒Barr virus-DNA; Human serum amyloid A;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4327 / 4338
页数：11
相关论文
共 50 条
  • [31] Predictive progression outcomes and risk stratification in patients with recurrent or metastatic nasopharyngeal carcinoma who received first-line immunochemotherapy
    Danjie He
    Yudong Zhang
    Shuiqing He
    Yuzhuo Zhang
    Keyao Dai
    Cheng Xu
    Ying Huang
    Clinical and Translational Oncology, 2024, 26 : 1209 - 1219
  • [32] Prognostic models for prediction of overall survival after first-line platinum-based chemotherapy for primary metastatic nasopharyngeal carcinoma.
    Li, Wang-Zhong
    Liu, Guo-Ying
    Liang, Hu
    Lv, Shu-Hui
    Lv, Xing
    Guo, Xiang
    Xia, Wei-Xiong
    Xiang Yanqun
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] REAL-WORD OUTCOMES OF MAINTENANCE CHEMOTHERAPY VERSUS AVELUMAB THERAPY AFTER FIRST-LINE INDUCTION CHEMOTHERAPY FOR ADVANCED UROTHELIAL CARCINOMA: YUSHIMA STUDY
    Izumi, Keita
    Tanaka, Hajime
    Yano, Masataka
    Takazawa, Ryoji
    Noro, Akira
    Tsukamoto, Tetsuro
    Yonese, Junji
    Okuno, Tetsuo
    Sakai, Yasuyuki
    Koga, Fumitaka
    Kageyama, Yukio
    Saito, Kazutaka
    Fujii, Yasuhisa
    JOURNAL OF UROLOGY, 2024, 211 (05): : E868 - E868
  • [34] Impact of duration of immunotherapy on clinical outcomes in advanced Merkel cell carcinoma patients responding to first-line immunotherapy
    Tachiki, Lisa M.
    Zawacki, Lauren
    Hippe, Daniel S.
    Moshiri, Yasman
    Alexander, Nora
    Akaike, Tomoko
    Doolittle-Amieva, Coley
    Pulliam, Thomas
    Zaba, Lisa C.
    Bhatia, Shailender
    Nghiem, Paul
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (10) : 2840 - 2840
  • [35] A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer
    Gravalos, Cristina
    Carrato, Alfredo
    Tobena, Maria
    Rodriguez-Garrote, Mercedes
    Soler, Gemma
    Ma Vieitez, Jose
    Robles, Luis
    Valladares-Ayerbes, Manuel
    Polo, Eduardo
    Luisa Limon, Ma
    Jose Safont, Ma
    Martinez de Castro, Eva
    Garcia-Alfonso, Pilar
    Aranda, Enrique
    CLINICAL COLORECTAL CANCER, 2018, 17 (02) : E323 - E329
  • [36] An International Multicentre Study of Consecutively Diagnosed Patients wSith ALCL: Outcomes Following First-Line Therapy in Routine Clinical Practice
    Martinez-Calle, Nicolas
    Kirkwood, Amy A.
    Lamb, Maxine
    Smith, Alexandra
    Manos, Kate
    Shrubsole, Caroline
    Gray, Nicola
    Ladani, Sapna
    Lewis, Katharine Louise
    Bishton, Mark
    Ahearne, Matthew J.
    Hawkes, Eliza A.
    Osborne, Wendy
    Collins, Graham P.
    Burton, Cathy
    Fox, Christopher P.
    BLOOD, 2019, 134
  • [37] Cost-effectiveness analysis of tislelizumab in combination with chemotherapy for the first-line treatment of patients with metastatic or recurrent nasopharyngeal carcinoma in China
    Tang, Yu-kai
    Xu, Zhe
    Ye, Zhuo-miao
    Li, Shi-ran
    Zhou, Qin
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2024, 46 (01): : 5 - 14
  • [38] Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-analysis of Randomized Controlled Trials
    Sun, Hong
    Bu, Fengjiao
    Li, Ling
    Zhang, Xiuwen
    Xin, Xiu
    Yan, Jingchao
    Huang, Taomin
    ANNALS OF PHARMACOTHERAPY, 2024, 58 (04) : 349 - 359
  • [39] Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study
    Rodriguez-Vida, A.
    Valderrama, B. P.
    Castellano, D.
    Pinto, A.
    Mellado, B.
    Puente, J.
    Climent, M. A.
    Domenech, M.
    Vazquez, F.
    Perez-Gracia, J. L.
    Bonfill, T.
    Morales-Barrera, R.
    Gonzalez-Billalabeitia, E.
    Garcia-del-Muro, X.
    Maroto, P.
    Navarro-Gorro, N.
    Juanpere, N.
    Juan, O.
    Bellmunt, J.
    ESMO OPEN, 2024, 9 (09)
  • [40] AVELUMAB FIRST-LINE MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA: LONG-TERM OUTCOMES FROM JAVELIN BLADDER 100 IN SUBGROUPS DEFINED BY FIRST-LINE CHEMOTHERAPY REGIMEN AND ANALYSIS OF OVERALL SURVIVAL FROM START OF FIRST-LINE CHEMOTHERAPY
    Sridhar, Srikala S.
    Powles, Thomas
    Gupta, Shilpa
    Climent Duran, Miguel A.
    Aragon-Ching, Jeanny B.
    Sternberg, Cora N.
    Cislo, Paul
    Costa, Nuno
    Salvo, Porto
    di Pietro, Alessandra
    Bellmunt, Joaquim
    Grivas, Petros
    JOURNAL OF UROLOGY, 2024, 211 (05): : E806 - E807
12345